Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IMMUNOTHERAPY

The emerging role of checkpoint inhibitors for rare genitourinary cancers

Rare genitourinary cancers have historically been challenging to treat given the scarcity in incidence, inadequacy of data on treatment and lack of general consensus to guide routine therapy. A phase II multicentre trial shows efficacy of nivolumab and ipilimumab in several cohorts of patients with rare genitourinary cancers.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Necchi, A., Pederzoli, F., Bandini, M. & Spiess, P. E. Revolutionizing care for rare genitourinary tumours. Nat. Rev. Urol. https://doi.org/10.1038/s41585-020-00402-8 (2020).

    Article  PubMed  Google Scholar 

  2. 2.

    Gandhy, S. U., Madan, R. A. & Aragon-Ching, J. B. The immunotherapy revolution in genitourinary malignancies. Immunotherapy 12, 819–831 (2020).

    CAS  Article  Google Scholar 

  3. 3.

    McGregor, B. A. et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer https://doi.org/10.1002/cncr.33328 (2020).

    Article  PubMed  Google Scholar 

  4. 4.

    Apolo, A. B. et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. J. Clin. Oncol. 38, 3672–3684 (2020).

    CAS  Article  Google Scholar 

  5. 5.

    Aggen, D. H. & Drake, C. G. Biomarkers for immunotherapy in bladder cancer: a moving target. J. Immunother. Cancer 5, 94 (2017).

    Article  Google Scholar 

  6. 6.

    Ramamurthy, C. et al. Molecular profiling of aggressive variant urothelial carcinoma. J. Clin. Oncol. 37 (Suppl. 7), 378 (2019).

    Article  Google Scholar 

  7. 7.

    Raj, N. et al. PD-1 blockade in advanced adrenocortical carcinoma. J. Clin. Oncol. 38, 71–80 (2020).

    CAS  Article  Google Scholar 

  8. 8.

    Le Tourneau, C. et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J. Immunother. Cancer 6, 111 (2018).

    Article  Google Scholar 

  9. 9.

    Tay, R. Y., Heigener, D., Reck, M. & Califano, R. Immune checkpoint blockade in small cell lung cancer. Lung Cancer 137, 31–37 (2019).

    Article  Google Scholar 

  10. 10.

    Motzer, R. J., McHenry, M. B. & Chen, A. C. Immune checkpoint blockade in advanced renal-cell carcinoma. N. Engl. J. Med. 379, 92–93 (2018).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jeanny B. Aragon-Ching.

Ethics declarations

Competing interests

J.B.A.-C. serves in the Speakers’ Bureau for Bristol Myers Squibb and serves on the advisory board of Pfizer, Merck and EMD Serono.

Additional information

Related links

ALLIANCE-led A031702 trial: https://clinicaltrials.gov/ct2/show/NCT03866382

Southwest Oncology Group (SWOG) trial 1609: https://clinicaltrials.gov/ct2/show/NCT02834013

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Aragon-Ching, J.B. The emerging role of checkpoint inhibitors for rare genitourinary cancers. Nat Rev Urol 18, 133–134 (2021). https://doi.org/10.1038/s41585-021-00426-8

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing